Interview with Garo H. Armen, Antigenics Chairman and CEO

Important notice regarding forward-looking statements

This interview contains forward-looking statements, including statements regarding the potential clinical benefit of Oncophage in melanoma, kidney cancer and other cancer indications that are based, in part, on subgroup analyses; the expectation that the survival data collected to date in the Oncophage kidney cancer trial are inconclusive and immature; the planned future data to be collected and analyzed in the Company’s Oncophage clinical trials and the timing for collecting and evaluating the data by the Company and regulatory authorities; the plans and timing for the conduct of additional Oncophage studies by the Company and its registration and related future revenue expectations; and knowledge concerning what needs to be accomplished to develop Oncophage and the dedication of the Company and its employees to achieve these objectives. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, unfavorable data resulting from analysis of clinical trial data; inability or limited ability to collect survival data from patients that withdrew from the study or were lost to follow-up in the Oncophage clinical trials; future survival data from patient monitoring in the Oncophage trial may not support further development or registration of the Oncophage; retention of key employees engaged in activities related to the future development of the Company’s products; decisions by regulatory agencies that delay or prevent further clinical trials of the Company’s products; the limited cash available to the Company to finance future clinical development of the Oncophage; imperfect knowledge regarding what needs to be accomplished to develop Oncophage; the ability to raise capital or enter into corporate partnering collaborations to finance future development of the Company’s products; and the factors described under Factors That May Impact Future Results in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics’ Form 10-Q as filed with the Securities and Exchange Commission on May 12, 2006. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this interview, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics’ business and securities, investors should give careful consideration to these risks and uncertainties.